ANI PHARMACEUTICALS, INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
ANI PHARMACEUTICALS, INC (ANIP) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $80.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-06-30 was $80.00K.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-12-31 was $0.00.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-09-30 was -$26.00K.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-06-30 was $0.00.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2025 was -$26.00K.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2024 was -$12.50M.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was -$12.50M.
- ANI PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $80.00K 10-Q · filed 2026-08-07 | $80.00K 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$26.00K derived: sum of 2 quarters · filed 2026-02-27 | -$26.00K derived: sum of 3 quarters · filed 2026-08-07 | -$26.00K 10-K · filed 2026-02-27 | |
| 2025-09-30 | -$26.00K 10-Q · filed 2025-11-07 | -$26.00K derived: sum of 2 quarters · filed 2026-08-07 | -$26.00K 10-Q · filed 2025-11-07 | -$26.00K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-07 | $0.00 10-Q · filed 2026-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-08-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | -$12.50M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | -$12.50M 10-Q · filed 2025-11-07 | -$25.00M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-08 | -$12.50M 10-Q · filed 2025-08-08 | -$25.00M derived: sum of 3 quarters · filed 2025-08-08 | -$25.00M derived: sum of 4 quarters · filed 2025-08-08 | |
| 2024-03-31 | -$12.50M 10-Q · filed 2025-05-09 | -$25.00M derived: sum of 2 quarters · filed 2025-05-09 | -$25.00M derived: sum of 3 quarters · filed 2025-05-09 | -$25.00M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | -$12.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$12.50M derived: sum of 2 quarters · filed 2025-02-28 | -$12.50M derived: sum of 3 quarters · filed 2025-02-28 | -$12.50M 10-K · filed 2025-02-28 | $12.50M 10-K · filed 2024-02-29 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | ||||
| 2022-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |